Alto Neuroscience Sees Unusually High Options Volume (NYSE:ANRO)

Alto Neuroscience, Inc. (NYSE:ANRO) saw unusually large options trading on Wednesday. Stock investors bought 2,129 call options on the company. This represents an increase of approximately 21% compared to the typical daily volume of 1,755 call options.

Alto Neuroscience Price Performance

Shares of NYSE ANRO opened at $4.36 on Thursday. The company has a current ratio of 19.85, a quick ratio of 19.85 and a debt-to-equity ratio of 0.04. The stock has a 50 day simple moving average of $12.22 and a 200-day simple moving average of $12.48. Alto Neuroscience has a 12-month low of $4.26 and a 12-month high of $24.00.

Alto Neuroscience (NYSE:ANRO) last released its earnings results on Tuesday, August 13th. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.07. On average, equities analysts expect that Alto Neuroscience will post -2.63 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Rodman & Renshaw lowered Alto Neuroscience from a “buy” rating to a “neutral” rating in a research report on Wednesday. Robert W. Baird lowered their price objective on Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating for the company in a report on Wednesday. Wedbush lowered Alto Neuroscience from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $29.00 to $4.00 in a report on Wednesday. Finally, William Blair reissued an “outperform” rating on shares of Alto Neuroscience in a report on Tuesday, September 10th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Alto Neuroscience currently has an average rating of “Moderate Buy” and a consensus price target of $24.40.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ANRO. RA Capital Management L.P. bought a new position in shares of Alto Neuroscience in the first quarter valued at $21,267,000. Price T Rowe Associates Inc. MD acquired a new stake in Alto Neuroscience during the 1st quarter valued at $9,788,000. Vanguard Group Inc. acquired a new stake in Alto Neuroscience during the 1st quarter valued at $8,233,000. Jennison Associates LLC acquired a new stake in Alto Neuroscience during the 1st quarter valued at $7,039,000. Finally, Artal Group S.A. acquired a new stake in Alto Neuroscience during the 1st quarter valued at $5,372,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.